Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Investment Insights
2015 Edition, Issue 2
No Status Quo:
The Difference
Disruption Makes
Out with the old, in with the new. People of nearly every era have probably surveyed the world
around them and marveled at how quickly things can change. But these days, change seems to be
setting a new speed record.
Seemingly overnight, products that were
once part of everyday life become relics of
a time gone by. Indeed, entire industries
are being disrupted by innovation or new
business models.
Change can be most apparent in the technology sector, where the status quo almost
seems to be a thing of the past. But its not
the only area where theres upheaval.
Key Takeaways
We live in a transformational time
Emerging technologies and innova-
Warp Speed: The Churn Rate for the S&P 500 Is Accelerating
Many companies have turned disruption into opportunity
Apple
Whole Foods
Amazon
Comcast
Walgreens
Sources: S&P Capital IQ; Standard & Poors Analysts Handbook, 1980, and Stocks in the Standard & Poors 500, 1982,
Standard & Poors Corporation; Dow Jones Newswires,
1987, Dow Jones; and Reuters.com, 2015, Thomson
Reuters. Standard & Poors 500 Composite IndexSM and
S&P 500 are service/trademarks owned by the McGrawHill Companies, Inc.
Supervalu
Under Armour
Chipotle
Hanes
eBay
Circuit City
Wendys
Palm
Avon
Netix
Monster Worldwide
RadioShack
Rite Aid
Sears
Eastman Kodak
The Cloud Isnt Really up in the Air, but the Potential Is Sky-High
So high, so fast: Amazon Web Services is the fastest growing business in the history of enterprise IT
2007: Salesforce.com
2005: VMware
1992: Cisco Systems
1988: Oracle
1986: Sun Microsystems
2,000
1953: IBM
Then: IBM ruled with the mainframe
0
0
4
Years
15%
US$900
% of U.S. in-store
retail volume
13
PayPal
31
30
18
(right scale)
Apple Pay
10
600
In-app
mobile
payment
172%
5
300
13
Google
Wallet 3
15
Softcard 3
13
CurrentC
Bitcoin
2014
2015
2016
2017
2018
35
28
13
13
(left scale)
18
Already accept
Plan to accept within 12 months
Plan to accept within 13 years
2019
40
20
0
AstraZeneca Abbott GlaxoSmith- Novartis Johnson &
Laboratories Kline
Johnson
Bayer
Eli Lilly
Merck
Pzer
BristolSano
Myers Squibb
Roche
12
10
32
17
37
22
23
31
38
77
12
21
16
36
16
66
32
29
58
48
79
big revenue streams at some pharmaceutical firms. The PD-1 and PD-L1
inhibitors remove cancers ability to hide
from the immune system.
Bristol-Myers Squibb and Merck have
1,200
Downloads
CDs
600
Cassettes
Vinyl
0
1973
1983
1993
2003
2013
materially from those expressed or implied in any forwardlooking statements made herein. We encourage you to consider
these and other factors carefully before making any investment
decisions and we urge you to avoid placing undue reliance on
forward-looking statements.